Common Contracts
2 similar null contracts by AgeX Therapeutics, Inc.
FORM OF PLEDGE AMENDMENTAgeX Therapeutics, Inc. • November 14th, 2023 • Pharmaceutical preparations
This Pledge Amendment, dated as of November 9, 2023, is delivered pursuant to Section 8.6 of the Amended and Restated Security Agreement, dated as of March 10, 2023 (as such agreement may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”) , by AgeX Therapeutics, Inc., a Delaware corporation, (the “Borrower”) and each of the other entities that party thereto, including pursuant to Section 8.6 thereof (together with the Borrower, the “Grantors” and each a “Grantor”), in favor of Juvenescence Limited, a company incorporated in the Isle of Man (the “Initial Lender”), in its capacity as the Lender under the Note (as defined in the Security Agreement) and as agent for itself and any other lender under the Note (in such agent capacity, together with its successors and permitted assigns, “Agent”). Capitalized terms used herein without definition are used as defined in the Security Agreement.
FORM OF PLEDGE AMENDMENTAgeX Therapeutics, Inc. • November 14th, 2023 • Pharmaceutical preparations
This Pledge Amendment, dated as of November 9, 2023, is delivered pursuant to Section 8.6 of the Amended and Restated Security Agreement, dated as of March 10, 2023 (as such agreement may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”) , by AgeX Therapeutics, Inc., a Delaware corporation, (the “Borrower”) and each of the other entities that party thereto, including pursuant to Section 8.6 thereof (together with the Borrower, the “Grantors” and each a “Grantor”), in favor of Juvenescence Limited, a company incorporated in the Isle of Man (the “Initial Lender”), in its capacity as the Lender under the Note (as defined in the Security Agreement) and as agent for itself and any other lender under the Note (in such agent capacity, together with its successors and permitted assigns, “Agent”). Capitalized terms used herein without definition are used as defined in the Security Agreement.
